fda glp-1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Pharmacovigilance Assessment of Compounded GLP-1
Description
While protein stimulates GLP-1 production (beneficial), certain amino acid patterns may also affect DPP-4 expression

The oral formulation is the most significant differentiator: if an oral tablet can produce weight loss comparable to injectable CagriSema, it could fundamentally change how dual pathway obesity therapy is delivered

PLoS One 9:e100778

This research was supported by National Natural Science Foundation of China (82271112)

For people who were on statins before starting semaglutide, the combined effect of the statin and semaglutide-mediated fat loss can sometimes move lipid markers significantly